Endometrial Cancer (Genetics)

Positive Results of Pre-Clinical Cancer Study Announced

Published in Women's Health Weekly, September 22nd, 1997

Findings from a pre-clinical study demonstrated that HER-2/neu gene amplification, on multivariate analysis, was predictive of poor outcome in the sub-set of patients studied with early stage endometrial cancer tumors.

Endometrial cancer is the most common gynecological cancer in the United States.

Jeffrey S. Ross, M.D., Oncor, Inc., Gaithersburg, Maryland, and colleagues at the Albany Medical College's Department of Pathology and Laboratory Medicine published the study results, which support the use of HER-2/neu gene amplification as a molecular marker in the evaluation of patients with endometrial cancer, in a recent issue of Molecular...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1997-09-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry